Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Nicotine increases colon cancer cell migration and invasion through epithelial to mesenchymal transition (EMT): COX-2 involvement.

Journal of cellular physiology | 2018

Cigarette smoking is a recognized risk factor for colon cancer and nicotine, the principal active component of tobacco, plays a pivotal role in increasing colon cancer cell growth and survival. The aim of this study was to determine the effect of nicotine on cellular Caco-2 and HCT-8 migration and invasion, focusing on epithelial to mesenchymal transition (EMT) induction, and COX-2 pathway involvement. In both these cell lines, treatment with nicotine increased COX-2 expression and the release of its enzymatic product PGE2 . Moreover, nicotine-stimulated cells showed increased migratory and invasive behavior, mesenchymal markers up-regulation and epithelial markers down-regulation, nuclear translocation of the β-catenin, increase of MMP-2 and MMP-9 activity, and enhanced NF-κB expression. Noticeably, all these effects are largely mediated by COX-2 activity, as simultaneous treatment of both cell lines with nicotine and NS-398, a selective COX-2 inhibitor, greatly reduced the number of migrating and invading cells and reverted nicotine-induced EMT. These findings emphasize that nicotine triggers EMT, leading hence to increased migration and invasiveness of colon cancer cells. Thereby, the use of COX-2 inhibitor drugs might likely counteract nicotine-mediated EMT effects on colon cancer development and progression.

Pubmed ID: 29215713 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Purified Mouse Anti-E-cadherin (antibody)

RRID:AB_397580

This monoclonal targets E-cadherin

View all literature mentions

beta-catenin (E-5) (antibody)

RRID:AB_626807

This monoclonal targets Raised against amino acids 680-781 mapping at the C-terminus of b-Cat o human origin

View all literature mentions

Anti-alpha smooth muscle Actin antibody (antibody)

RRID:AB_2223021

This polyclonal targets alpha smooth muscle Actin

View all literature mentions

Cox2 (D5H5) XP® Rabbit mAb (antibody)

RRID:AB_2571729

This recombinant monoclonal targets Cox2

View all literature mentions

Fascin 1 (D-10) (antibody)

RRID:AB_627582

This monoclonal targets FSCN1

View all literature mentions

HCT 8 (cell line)

RRID:CVCL_2478

Cell line HCT 8 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Caco-2 (cell line)

RRID:CVCL_0025

Cell line Caco-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Purified Mouse Anti-E-cadherin (antibody)

RRID:AB_397580

This monoclonal targets E-cadherin

View all literature mentions

beta-catenin (E-5) (antibody)

RRID:AB_626807

This monoclonal targets Raised against amino acids 680-781 mapping at the C-terminus of b-Cat o human origin

View all literature mentions